Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6451 to 6465 of 7707 results

  1. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued [GID-TA10546]

    Technology appraisal guidance
    Discontinued

  2. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued [GID-TA10355]

    Technology appraisal guidance
    Discontinued

  3. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued [GID-TA10081]

    Technology appraisal guidance
    Discontinued

  4. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued [GID-TA10087]

    Technology appraisal guidance
    Discontinued

  5. Seven day working

    Discontinued [GID-QS10108]

    Quality standard
    Discontinued

  6. Mental health community settings

    Discontinued [GID-SGWAVE0702]

    Safe staffing guideline
    Discontinued

  7. OraQuick® HCV Rapid Antibody Test (discontinued)

    Discontinued [GID-MT117]

    Medical technologies guidance
    Discontinued

  8. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued [GID-MT510]

    Medical technologies guidance
    Discontinued

  9. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued [GID-TA10702]

    Technology appraisal guidance
    Discontinued

  10. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development [GID-TA10577] Expected publication date: 21 April 2021

    Technology appraisal guidance
    In development

  11. Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]

    In development [GID-TA10780] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

    Discontinued [GID-TA10088]

    Technology appraisal guidance
    Discontinued

  13. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development [GID-TA10592] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

    In development [GID-TA10483] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ex utero intrapartum therapy for fetal obstruction

    Discontinued [GID-IP1156]

    Interventional procedures guidance
    Discontinued